BioCentury
ARTICLE | Clinical News

Signifor pasireotide regulatory update

November 12, 2012 8:00 AM UTC

FDA's Endocrinologic and Metabolic Drugs Advisory committee voted 10-0 that efficacy and safety data for pasireotide from Novartis support approval to treat Cushing's disease. Novartis submitted the a...